Upon administration, MCC950 inhibited fibrillar α-synuclein-induced NLRP3 activation and reduced dopaminergic neuron degeneration, aggregation of α-synuclein, and the motor symptoms experienced by the PD mice (Gordon et al., 2018). Here, NLRP3 is linked to Parkinson disease.